Novel Intervention Relieves Depression in MS Patients

An internet-based cognitive-behavioral therapy (iCBT) program specifically designed for patients with multiple sclerosis (MS) significantly reduced depressive symptoms compared to usual treatment, new research shows. Participants in the randomized controlled trial who received iCBT either benefits alone or in combination with weekly emails from therapists reported that persisted up to a year after therapy. Although … Read more

Single Dose of Psilocybin for Major Depression Tied to Short-Term Remission

A single 25 mg dose of synthetic psilocybin in combination with psychotherapy appears to effectively ease symptoms of treatment-resistant depression (TRD) — at least in the short-term, new research shows. In the largest study of psilocybin for TRD to-date, results of the phase 2b randomized, double-blind trial show participants in the 25-mg dose group experienced … Read more

Major Depression Treatments Boost Brain Connectivity

VIENNA — Inpatient treatment for major depressive disorder (MDD) can lead to brain connectivity increases that are associated with degree of symptom improvement, new research suggests. In a “repeat” MRI study, adult participants with MDD had significantly lower brain connectivity compared with their healthy peers at baseline — but showed significant improvement at the 6-week … Read more

1 in 7 Mortality Postsurgery; ECT and MDE; and Monkeypox News

One in Seven Older Adults Die Within 1 Year After Surgery One in seven older adults die within 1 year of major surgery. The risk for mortality is higher among people older than 80 years or who are frail or may have dementia, according to a new study of community-living individuals. The study did not … Read more

ECT Tops Ketamine for Major Depression

Electroconvulsive therapy (ECT) is more effective than intravenous (IV) ketamine for patients experiencing a major depressive episode (MDE) in new findings that are in line with the KetECT study ― the first head-to-head trial of ketamine and ECT. As reported by Medscape Medical News, the KetECT trial was published earlier this year. It showed that … Read more

Healthy Diet, Less News Key to Preventing Anxiety During COVID

VIENNA — Following a healthy, balanced diet and avoiding excessive consumption of stressful news helped prevent anxiety and depressive symptoms during the COVID-19 pandemic, new research suggests. Results from a longitudinal Spanish survey study of more than 1000 adults showed that being outside, relaxing, participating in physical activities, and drinking plenty of water were also … Read more

Antibiotic May Enhance TMS, Improve Depression Outcomes

Administering D-cycloserine (DCS) along with transmagnetic stimulation (TMS) may be a promising strategy to improve outcomes in major depressive disorder (MDD), new research suggests. “The take-home message is that this proof-of-concept study opens up a new avenue of treatment research so that in the future, we may be able to provide our patients with safe … Read more

Home-Based Transcranial Stimulation Succeeds for Major Depression

Home-based transcranial direct current stimulation with real-time supervision significantly improved clinical symptoms of major depressive disorder, based on data from 26 individuals. Major depressive disorder (MDD) remains a leading cause of disability and a significant predictor of suicide worldwide, Rachel D. Woodham, PhD, of the University of East London and colleagues wrote. Transcranial direct current … Read more

‘Disturbing’ Lack of Follow-up Care After a Psychiatric Crisis

There is a concerning lack of follow-up care for young people who experience a mental health crisis, new research suggests. Results from a large database study showed less than half of youth and young adults hospitalized for a psychiatric event received follow-up care within 7 days. The follow-up rate was less than 30% for those … Read more

Self-Worth Training Boosts Ketamine’s Effects in Severe Depression

A simple computer-based neurocognitive training program that emphasizes self-worth can extend the antidepressant effects of ketamine for up to 30 days in patients with treatment-resistant depression (TRD), new research suggests. The double-blind, randomized clinical trial is the first to assess combining ketamine with a low-cost protective learning program, researchers note. They add that the findings … Read more